Dyslipidemia in HIV-infected individuals

Brazilian Journal of Infectious Diseases

Volumn 14, Issue 6, 2010, Pages 575-588

  Sprinz, Eduardo ^a   Lazzaretti, Rosmeri Kuhmmer ^b   Kuhmmer, Regina ^a   Ribeiro, Jorge Pinto ^a  

^a HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

^b FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

Author keywords

Combined antiretroviral therapy; Dyslipidemia; HIV AIDS; Nutrition, public health

Indexed keywords

ABACAVIR; ALPHA TOCOPHEROL; ANTILIPEMIC AGENT; ANTIRETROVIRUS AGENT; ATORVASTATIN; BEZAFIBRATE; EFAVIRENZ; EZETIMIBE; FENOFIBRATE; FIBRIC ACID DERIVATIVE; FISH OIL; FLUINDOSTATIN; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOPINAVIR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; NEVIRAPINE; NICOTINIC ACID; OMEGA 3 FATTY ACID; PLACEBO; PRAVASTATIN; PROTEINASE INHIBITOR; RITONAVIR; ROSUVASTATIN; SIMVASTATIN; TENOFOVIR; TRIACYLGLYCEROL; UNINDEXED DRUG;

ABSENCE OF SIDE EFFECTS; ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CORONARY ARTERY DISEASE; DIET SUPPLEMENTATION; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG METABOLISM; DRUG SAFETY; DYSLIPIDEMIA; EDUCATION PROGRAM; HIV ASSOCIATED LIPODYSTROPHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERLIPIDEMIA; HYPERTRIGLYCERIDEMIA; LIFESTYLE MODIFICATION; PATHOGENESIS; TRIACYLGLYCEROL BLOOD LEVEL;

ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DYSLIPIDEMIAS; HIV INFECTIONS; HUMANS; HYPOLIPIDEMIC AGENTS; RISK FACTORS;

EID: 79955954868     PISSN: 14138670     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1413-8670(10)70115-X     Document Type: Article

References (80)

1. Palella F.J., Delaney K.M., Moorman A.C., et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998, 338:853-860.
2. Tuboi S.H., Brinkhof M.W.G., Egger M., et al. Discordant responses to potent antiretroviral treatment in previously naive HIV-1-infected adults initiating treatment in resource-constrained countries: the antiretroviral therapy in low-income countries (ART-LINC) collaboration. J Acquir Immune Defic Syndr 2007, 45:52-59.
3. Marins J.R., Jamal L.F., Chen S.Y., et al. Dramatic improvement in survival among adult Brazilian AIDS patients. AIDS 2003, 17:1675-1682.
4. Braitstein P., Brinkhof M.W., Dabis F., et al. Mortality of HIV- 1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries. Lancet 2006, 367:817-824.
5. Fang C.T., Chang Y.Y., Hsu H.M., et al. Life expectancy of patients with newly-diagnosed HIV infection in the era of highly active antiretroviral therapy. Q J Med 2007, 100:97-105.
6. Lohse N., Hansen A.B., Gerstoft J., Obel N. Improved survival in HIV-infected persons: consequences and perspectives. J Antimicrob Chemother 2007, 60:461-463.
7. Carr A., Sâmaras K., Burton S., et al. A syndrome of peripheral lipodystrophy, hyperlipidemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998, 12:51-58.
8. Mattevi V.S., Gasparotto A.S., Lazzaretti R.K., et al. Apolipoprotein B gene polymorphisms are associated with higher cholesterol levels in HIV-infected individuals on HAART. Antiviral Therapy 2009, 14(suppl 2):A52.
9. Noor M.A. The role of protease inhibitors in the pathogenesis of HIV-associated insulin resistance: cellular mechanisms and clinical implications. Curr HIV/AIDS Rep 2007, 4:126-134.
10. Maagaard A., Kvale D. Mitochondrial toxicity in HIV-infected patients both off and on antiretroviral treatment: a continuum or distinct underlying mechanisms?. J Antimicrob Chemother 2009, 64:901-909. Epub 2009 Sep 9.
11. Côté H.C. Mechanisms of antiretroviral therapy-induced mitochondrial dysfunction. Curr Opin HIV AIDS 2007, 2(4):253-260. Jul.
12. Carr A., Cooper D.A. Adverse effects of antiretroviral therapy. Lancet 2000, 356:1423-1430.
13. Friis-Møller N., Sabin C.A., Weber R., et al. Cardiovascular disease risk factors in HIV patients-association with antiretroviral therapy. Results from the DAD study. AIDS 2003, 17:1179-1193.
14. Sabin C.A., Worm S.W., et al. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration. Lancet 2008, 371:1417-1426. D:A:D Study Group.
15. Grinspoon S., Carr A. Cardiovascular risk and body-fat abnormalities in HIV-infected adults. N Engl J Med 2005, 352:48-62.
16. Carr A., Samaras K., Thorisdottir A., et al. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. Lancet 1999, 353:2093-2099.
17. Gervasoni C., Ridolfo A.L., Trifiro G., et al. Redistribution of body fat in HIV-infected women undergoing combined antiretroviral therapy. AIDS 1999, 13:465-471.
18. Safrin S., Grunfeld C. Fat Distribution and metabolic changes in patients with HIV infection. AIDS 1999, 13:2493-2505.
19. Grunfeld C., Tien P. Difficulties in understanding the metabolic complications of acquired immune deficiency syndrome. Clin Infect Dis 2003, 37:43-46.
20. Asztalos B.F., Schaefer E.J., Horvath K.V., et al. Protease inhibitor-based HAART, HDL CHD-risk in HIV-infected patients. Atherosclerosis 2006, 184:72-77.
21. Stein J.H., Klein M.A., Bellehumeur J.L., et al. Use of human immunodeficiency virus-1 protease inhibitors is associated with atherogenic lipoprotein changes and endothelial dysfunction. Circulation 2001, 104:257-262.
22. Grunfeld C., Pang M., Doerrler W., et al. Lipids, lipoproteins, triglyceride clearance, and cytokines in human immunodeficiency virus infection and the acquired immunodeficiency syndrome. J Clin Endocrinol Metab 1992, 74:1045-1052.
23. Zangerle R., Sarcletti M., Gallati H., et al. Decreased plasma concentrations of HDL cholesterol in HIV-infected individuals are associated with immune activation. J Acquir Immune Defic Syndr 1994, 7:1149-1156.
24. Dubé M.P., Stein J.H., Aberg J.A., et al. Guidelines for the evaluation and management of dyslipidemia in human immunodeficiency virus (HIV)-infected adults receiving antiretroviral therapy: Recommendations of the HIV Medicine Association of the Infectious Disease Society of America and the Adult AIDS Clinical Trials Group. Clin Infect Dis 2003, 37:613-627.
25. Mooser V., Carr A. Antiretroviral therapy-associated hyperlipidaemia in HIV disease. Curr Opin Lipidol 2001, 12:313-319.
26. Riddle T.M., Kuhel D.G., Woollett L.A., et al. HIV protease inhibitor induces fatty acid and sterol biosynthesis in liver and adipose tissues due to the accumulation of activated sterol regulatory element-binding proteins in the nucleus. J Biol Chem 2001, 276:37514-37519.
27. Liang J.S., Distler O., Cooper D.A., et al. HIV protease inhibitors protect apolipoprotein B from degradation by the proteasome: a potential mechanism for protease inhibitor-induced hyperlipidemia. Nat Med 2001, 7:1327-1331.
28. Grunfeld C., Doerrler W., Pang M., et al. Abnormalities of apolipoprotein E in the acquired immunodeficiency syndrome. J Clin Endocrinol Metab 1997, 82:3734-3740.
29. Shahmanesh M., Jaleel H., DeSilva Y., et al. Protease inhibitor related type III hyperlipoproteinaemia is common and not associated with apolipoprotein-E E2/E2 phenotype. Sex Transm Infect 2001, 77:283-286.
30. Hertel J., Struthers H., Horj C.B., Hruz P.W. A structural basis for the acute effects of HIV protease inhibitors on GLUT4 intrinsic activity. J Biol Chem 2004, 279:55147-55152.
31. Murata H., Hruz P.W., Mueckler M. Indinavir inhibits the glucose transporter isoform Glut4 at physiologic concentrations. AIDS 2002, 16:859-863.
32. Bastard J.P., Caron M., Vidal H., et al. Association between altered expression of adipogenic factor SREBP1 in lipoatrophic adipose tissue from HIV-1-infected patients and abnormal adipocyte differentiation and insulin resistance. Lancet 2002, 359:1026-1031.
33. Mynarcik D.C., Combs T., McNurlan M.A., et al. Adiponectin and leptin levels in HIV-infected subjects with insulin resistance and body fat redistribution. J Acquir Immune Defic Syndr 2002, 31:514-520.
34. Tontonoz P., Hu E., Spiegelman B.M. Regulation of adipocyte gene expression and differentiation bt peroxisome proliferator activated receptor c. Curr Opin Genet Dev 1995, 5:571-576.
35. Brinkman K., Smeitink J.A., Romijn J.A., Reiss P. Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy- related lipodystrophy. Lancet 1999, 354:1112-1115.
36. Nolan D., Hammond E., Martin A., et al. Mitochondrial DNA depletion and morphologic changes in adipocytes associated with nucleoside reverse transcriptase inhibitor therapy. AIDS 2003, 17:1329-1338.
37. Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med 2007, 356:1723-1735. The DAD Study Group.
38. Triant V.A., Lee H., Hadigan C., Grinspoon S.K. Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease. J Clin Endocrinol Metab 2007, 92:2506-2512.
39. Bozzette S.A., Ake C.F., Tam H.K., et al. Cardiovascular and cerebrovascular events in patients treated for human immunodeficiency virus infection. N Engl J Med 2003, 348:702-710.
40. Law M.G., Friis-Møller N., El-Sadr W.M., et al. The use of the Framingham equation to predict myocardial infarctions in HIV-infected patients: comparison with observed events in the DAD Study. HIV Medicine 2006, 7:218-230.
41. El-Sadr W.M., Lundgren J.S., Neaton J.D. CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med 2006, 355:2283-2296.
42. Martinez E., García-Viejo M.A., Blanco J.L., et al. Impact of switching from human immunodeficiency virus type 1 protease inhibitors to efavirenz in successfully treated adults with lipodystrophy. Clin Infect Dis 2000, 31:1266-1273.
43. Calza L., Manfred R., Chiodo F. Dyslipidaemia associated with antiretroviral therapy in HIV-infected patients. J Antimicrob Chemother 2004, 53:10-14.
44. Savês M., Raffi F., Capeau J., et al. Factors related to lipodystrophy and metabolic alterations in patients with human immunodeficiency virus infection receiving highly active antiretroviral therapy. Clin Infect Dis 2002, 34:1396-1405.
45. Guimarães A.C., Lima M., Mota E., et al. The cholesterol level of a selected level of a selected Brazilian salaried population: biological and socioeconomic influences. Cardiovascular Disease Prevention 1998, 1:306-317.
46. Tang J.L., Armitage J.M., Lancaster T., et al. Systematic review of dietary intervention trials to lower blood total cholesterol in free-living subjects. BMJ 1998, 316:1213-1220.
47. Yu-Poth S., Zhao G., Etherton T., et al. Effects of the National Cholesterol Education Programs Step I and Step II dietary intervention programs on cardiovascular disease risk factors: a meta-analysis. Am J Clin Nutr 1999, 69:632-646.
48. Jones S.P., Doran D.A., Leatt P.B., et al. Short-term exercise training improves body composition and hyperlipidaemia in HIV-positive individuals with lipodystrophy. AIDS 2001, 2049-2051.
49. Terry L., Sprinz E., Stein R., et al. Exercise training in HIV-1-infected individuals with dyslipidemia and lipodystrophy. Med Sci Sports Exerc 2006, 38:411-417.
50. Fitch K.V., Anderson E.J., Hubbard J.L., et al. Effects of a lifestyle modification program in HIV-infected patients with the metabolic syndrome. AIDS 2006, 20:1843-1850.
51. Hadigan C., Jeste S., Anderson E.J., et al. Modifiable dietary habits and their relation to metabolic abnormalities in men and women with human immunodeficiency virus infection and fat redistribution. Clin Infect Dis 2001, 33:710-717.
52. Batterham M.J., Brown D., Workman C. Modifying dietary fat intake can reduce serum cholesterol in HIV-associated hypercholesterolemia. AIDS 2002, 17:1414-1416.
53. Batterham M.J., Garsia R., Greenop P.A. Dietary intake, serum lipids, insulin resistance and body composition in the era of highly active antiretroviral therapy Diet FRS Study. AIDS 2000, 14:1839-1843.
54. Barrios A., Blanco F., García-Benayas T., et al. Effect of dietary intervention on highly active antiretroviral therapy-treated dyslipidemia. AIDS 2002, 16:2079-2081.
55. Shah M., Tierney K., Adams-Huet B., et al. The role of diet, exercise and smoking in dyslipidaemia in HIV-infected patients with lipodystrophy. HIV Med 2005, 6:291-298.
56. Bang H.O., Dyerberg J., Sinclair H.M. The composition of the Eskimo food in north western Greenland. Am J Clin Nutr 1980, 33:2657-2661.
57. Wohl D.A., Tien H.C., Busby M., et al. Randomized study of the safety and efficacy of fish oil (omega-3 fatty acid) supplementation with dietary and exercise counseling for the treatment of antiretroviral therapy-associated hypertriglyceridemia. Clin Infect Dis 2005, 41:1498-1504.
58. Gerber J.G., Kitch D.W., Fichtenbaum C.J., et al. Fish oil and fenofibrate for the treatment of hypertriglyceridemia in HIV-infected subjects on antiretroviral therapy: results of ACTG A5186. J Acquir Immune Defic Syndr 2008, 47:459-466.
59. De Truchis P., Kirstetter M., Perier A., et al. Reduction in triglyceride level with N-3 polyunsaturated fatty acids in HIV-infected patients taking potent antiretroviral therapy: a randomized prospective study. J Acquir Immune Defic Syndr 2007, 44:278-285.
60. Calza L., Manfredi R., Chiodo F. Statins and fibrates for the treatment of hyperlipidaemia in HIV-infected patients receiving HAART. AIDS 2003, 17:851-859.
61. Martínez E., Leyes P., Ros E. Effectiveness of lipid-lowering therapy in HIV patients. Curr Opin HIV AIDS 2008, 3:240-246.
62. Henry K., Melroe H., Huebesch J., et al. Atorvastatin and gemfibrozil for protease-inhibitor-related lipid abnormalities. Lancet 1998, 352:1031-1032.
63. Miller J., Brown D., Amin J., et al. A randomized, double-blind study of gemfibrozil for the treatment of protease inhibitor-associated hypertriglyceridemia. AIDS 2002, 16:2195-2200.
64. Calza L., Manfredi R., Colangeli V., et al. Substitution of nevirapine or efavirenz for protease inhibitor versus lipid-lowering therapy for the management of dyslipidaemia. AIDS 2005, 19:1051-1058.
65. Hajjar L.A., Carleraro D., Yu P.C., et al. Cardiovascular manifestations in patients infected with the human immunodeficiency virus. Arq Bras Cardiol 2005, 85:363-377.
66. Van der Lee M., Sabkatsing R., Schippers E., et al. Pharmacokinetics and pharmacodynamics of combined use of lopinavir/ritonavir and rosuvastatin in HIV-infected patients. Antivir Ther. 2007, 12:1127-1132.
67. Palacios R., Santos J., González M., et al. Efficacy and Safety of Atorvastatin in the Treatment of Hypercholesterolemia Associated With Antiretroviral Therapy. J Acquir Immune Defic Syndr 2002, 30:536-537.
68. Coll B., Aragonés G., Parra S., et al. Ezetimibe effectively decreases LDL-cholesterol in HIV-infected patients. AIDS 2006, 20:1675-1677.
69. Negredo E., Ribalta J., Paredes R., et al. Reversal of atherogenic lipoprotein profile in HIV-1 infected patients with lipodystrophy after replacing protease inhibitors by nevirapine. AIDS 2002, 16:1383-1389.
70. Bennett M.T., Johns K.W., Bondy G.P. Ezetimibe is effective when added to maximally tolerated lipid lowering therapy in patients with HIV. Lipids Health Dis 2007, 6:15.
71. Calza L., Manfredi R., Chiodo F. Use of fibrates in the management of hyperlipidaemia in HIV-infected patients receiving HAART. Infection 2002, 30:26-31.
72. Miller J., Brown D., Amin J., et al. A randomised, double-blind study of gemfibrozil for the treatment of protease inhibitorassociated hypertriglyceridaemia. AIDS 2002, 16:2195-2200.
73. Badiou S., De Boever C.M., Dupuy A., et al. Fenofibrate improves the atherogenic lipid profile and enhances LDL resistance to oxidation in HIV-positive adults. Atherosclerosis 2004, 172:273-279.
74. Mallon P.W.G., Miller J., Kovacic J.C., Kent-Hughes J., Norris R., Samaras K., Feneley M.P., Cooper D.A., Carr A. Effect of pravastatin on body composition and markers of cardiovascular disease in HIV-infected Men a randomized, placebo-controlled study. AIDS 2006, 20:1003-1010.
75. Negredo E., Moltó J., Puig J., et al. Ezetimibe, a promising lipid-lowering agent for the treatment of dyslipidaemia in HIV-infected patients with poor response to statins. AIDS 2006, 20:2159-2164.
76. Fisac C., Fumero E., Crespo M., et al. Metabolic benefits 24 months after replacing a protease inhibitor with abacavir, efavirenz or nevirapine. AIDS 2005, 19:917-925.
77. Keiser P.H., Sension M.G., DeJesus E., et al. Substituting abacavir for hyperlipidemia-associated protease inhibitors in HAART regimens improves fasting lipid profiles, maintains virologic suppression, and simplifies treatment. BMC Infect Dis 2005, 5:2.
78. Moyle G.J., Sabin C.A., Cartledge J., et al. A randomized comparative trial of tenofovir DF or abacavir as replacement for a thymidine analogue in persons with lipoatrophy. AIDS 2006, 20:2043-2050.
79. Llibre J.M., Domingo P., Palacios R., et al. Sustained improvement of dyslipidaemia in HAART treated patients replacing stavudine with tenofovir. AIDS 2006, 20:1407-1414.
80. Milinkovic A., Martinez E., López S., et al. The impact of reducing stavudine dose versus switching to tenofovir on plasma lipids, body composition and mitochondrial function in HIV-infected patients. Antivir Ther 2007, 12:407-415.